Public Profile

Astellas

Astellas Pharma Inc., commonly referred to as Astellas, is a leading global pharmaceutical company headquartered in Tokyo, Japan. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative medicines, Astellas focuses on areas such as oncology, urology, immunology, and neuroscience. The company is renowned for its commitment to research and development, which has led to the introduction of unique therapies that address unmet medical needs. Astellas has achieved notable market recognition, consistently ranking among the top pharmaceutical firms worldwide, thanks to its dedication to improving patient outcomes and advancing healthcare solutions.

DitchCarbon Score

How does Astellas's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

47

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Astellas's score of 47 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Astellas's reported carbon emissions

In 2023, Astellas Pharma Inc., headquartered in Japan, reported total greenhouse gas emissions of approximately 1,222,500,000 kg CO2e globally. This includes 59,203,000 kg CO2e from Scope 1 emissions and 63,047,000 kg CO2e from Scope 2 emissions. Notably, their Scope 3 emissions were significantly higher, amounting to about 1,121,350,000 kg CO2e. Astellas has set ambitious climate commitments, aiming to achieve net-zero greenhouse gas emissions across all scopes by 2050. In the near term, they target a 63% reduction in Scope 1 and 2 emissions by FY2030, using 2015 as the base year. Additionally, they plan to reduce Scope 3 emissions by 37.5% by FY2030, also relative to the 2015 baseline. These targets align with the 1.5°C climate goal, demonstrating Astellas's commitment to addressing climate change effectively.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20052011201220132014201520162017201820192020202120222023
Scope 1
108,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
-
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Astellas's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Astellas is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Astellas is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Intas

IN
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Accord Healthcare, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Meda AB

SE
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Roche Holding AG

CH
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Bayer Pharma AG

DE
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Hospira

US
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers